Sonia Quaratino
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies.
Journal: Journal for immunotherapy of cancer
Published: April 27, 2026
Author Correction: Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition.
Journal: Nature cell biology
Published: February 23, 2026
Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial.
Journal: The British journal of dermatology
Published: April 21, 2023
OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005.
Journal: Clinical pharmacology and therapeutics
Published: October 13, 2021
An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression.
Journal: Cancer immunology research
Published: January 14, 2020
Activation-induced cell death of self-reactive regulatory T cells drives autoimmunity.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: December 11, 2019
Prospects for combining targeted and conventional cancer therapy with immunotherapy.
Journal: Nature reviews. Cancer
Published: March 25, 2017
New Approaches in Immunotherapy for the Treatment of Lung Cancer.
Journal: Current topics in microbiology and immunology
Published: December 20, 2014
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 17, 2014
NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy.
Journal: Journal of translational medicine
Published: October 03, 2014
miR-19-Mediated Inhibition of Transglutaminase-2 Leads to Enhanced Invasion and Metastasis in Colorectal Cancer.
Journal: Molecular cancer research : MCR
Published: August 19, 2014
Last Updated: 09/26/2026